Chugai returned emugrobart rights and Chugai Pharmaceutical stock costs EUR 34.54

Published on 10/08/2026 at 10:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Citi keeps Buy with a JPY 11,100.00 target on October 7, 2026. Chugai Pharmaceutical stock stood at EUR 34.54 on October 8, 2026 after EUR 34.61.

Chugai Pharmaceutical, JP3519400000, Illustration mit AI erstellt.

Chugai Pharmaceutical stock stood at EUR 34.54 at Lang & Schwarz on October 8, 2026 at 10:07 a.m. CEST, while Chugai had returned emugrobart rights after ending its obesity program on September 28, 2026. The company is preparing to resume development of the drug for spinal muscular atrophy.

Emugrobart changes direction

According to Chugai Pharmaceutical on September 28, 2026, Roche ended future development of emugrobart, also known as GYM329, for obesity and returned all related rights to Chugai. The decision followed an interim analysis of the Phase II GYMINDA study, which indicated that clinically meaningful weight loss was unlikely to meet the prespecified objectives.

Chugai said emugrobart was well tolerated and that the study produced no new safety signals. It also said the announcement was not expected to affect its consolidated financial forecast for fiscal year 2026, making the development shift more important for the pipeline than for near-term earnings.

Results and analyst target

For the second quarter of 2026, revenue reached JPY 341.58 billion, up 17.80 percent from JPY 290.01 billion a year earlier, while net profit rose to JPY 116.33 billion from JPY 97.16 billion. Markets Insider reported the figures on October 7, 2026.

The same report said Citi maintained a Buy rating and a JPY 11,100.00 price target on October 7, 2026. That target is a separate yen-based analyst reference, not a replacement for the euro quotation used in this article.

Next results date is October 27

Chugai's investor-relations calendar lists third-quarter fiscal 2026 results for October 27, 2026, with a conference scheduled for the same date, according to Chugai Pharmaceutical. The upcoming report will test whether the strong first-half revenue trend remains intact while investors assess the next steps for emugrobart.

At Lang & Schwarz, Chugai was trading at EUR 34.54 on October 8, 2026 at 10:07 a.m. CEST, down 0.20 percent versus the Lang & Schwarz prior close of EUR 34.61 on October 7, 2026. The Tokyo Stock Exchange listing had a 52-week range of JPY 5,974.00 to JPY 10,700.00 and a market capitalization of JPY 10.1 trillion as of October 8, 2026. The further course of trading is shown by the continuously updated real-time quote of Chugai Pharmaceutical stock.